- Home
- SAGE vs SOR Comparison
SAGE vs SOR Comparison
Compare SAGE & SOR Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.
- Machine Learning Prediction
- ML Decision
- SAGE
- SOR
- Stock Information
- Founded
- SAGE 2010
- SOR 1968
- Country
- SAGE United States
- SOR United States
- Employees
- SAGE N/A
- SOR N/A
- Industry
- SAGE Biotechnology: Pharmaceutical Preparations
- SOR Investment Managers
- Sector
- SAGE Health Care
- SOR Finance
- Exchange
- SAGE Nasdaq
- SOR Nasdaq
- Market Cap
- SAGE 413.9M
- SOR 348.3M
- IPO Year
- SAGE 2014
- SOR N/A
- Fundamental
- Price
- SAGE $9.30
- SOR $42.53
- Analyst Decision
- SAGE Hold
- SOR
- Analyst Count
- SAGE 18
- SOR 0
- Target Price
- SAGE $10.06
- SOR N/A
- AVG Volume (30 Days)
- SAGE 2.4M
- SOR 16.2K
- Earning Date
- SAGE 07-30-2025
- SOR 01-01-0001
- Dividend Yield
- SAGE N/A
- SOR 7.24%
- EPS Growth
- SAGE N/A
- SOR N/A
- EPS
- SAGE N/A
- SOR 6.50
- Revenue
- SAGE $47,404,000.00
- SOR N/A
- Revenue This Year
- SAGE $102.21
- SOR N/A
- Revenue Next Year
- SAGE $43.01
- SOR N/A
- P/E Ratio
- SAGE N/A
- SOR $6.41
- Revenue Growth
- SAGE N/A
- SOR N/A
- 52 Week Low
- SAGE $4.62
- SOR $36.41
- 52 Week High
- SAGE $13.47
- SOR $42.75
- Technical
- Relative Strength Index (RSI)
- SAGE 78.92
- SOR 57.82
- Support Level
- SAGE $6.44
- SOR $42.30
- Resistance Level
- SAGE $9.33
- SOR $43.28
- Average True Range (ATR)
- SAGE 0.26
- SOR 0.44
- MACD
- SAGE 0.33
- SOR -0.03
- Stochastic Oscillator
- SAGE 98.98
- SOR 64.44
About SAGE Sage Therapeutics Inc.
Sage Therapeutics Inc is a clinical-stage biopharmaceutical company focused on brain health medicines. The company is targeting diseases and disorders of the brain with three key focus areas: depression, neurology and neuropsychiatry; also targeting two critical central nervous system, or CNS, receptor systems, GABA and NMDA. Its products ZURZUVAE is a medicine for the treatment of postpartum depression, or PPD, in adults, and ZULRESSO is a CIV injection for the treatment of postpartum depression in individuals 15 years old and older. It also has other drugs in its pipeline such as SAGE-324, Dalzanemdor (SAGE-718) among others.
About SOR Source Capital Inc.
Source Capital Inc is a diversified, closed-end management investment company. The investment objective of the company is to seek maximum total return for Common shareholders from both capital appreciation and investment income to the extent consistent with the protection of invested capital.